Backed by robust preclinical data, RES-010 is currently being evaluated in a Phase 1 clinical trial, positioning Resalis Therapeutics as a key company in the evolving landscape of obesity treatment.
We applied our deep understanding of metabolic diseases and the ncRNA modality to develop our lead candidate, RES-010. We are advancing RES-010 toward clinical evaluation initially in obesity and fatty liver disease.
Members of our management team will be at:
hosted by the Harvard Medical School Initiative for RNA Medicine
April 23-25, Boston
1st EASD Early Career Academy Meeting
April 28-30, Pisa, Italy
